budesonide + doxofylline

Budesonide + doxofylline is a fixed-dose combination of two active pharmaceutical ingredients used primarily in the management of bronchial asthma and chronic obstructive pulmonary disease (COPD). Budesonide is an inhaled synthetic glucocorticoid corticosteroid that acts as an anti-inflammatory agent by binding to the glucocorticoid receptor, reducing airway inflammation. Doxofylline is a methylxanthine derivative with bronchodilator and anti-inflammatory properties; it inhibits phosphodiesterase enzymes (PDE3 and PDE4), increases cyclic AMP levels, relaxes bronchial smooth muscle, and modulates inflammatory responses. The combination aims to provide both anti-inflammatory effects from budesonide and bronchodilation plus steroid-sparing effects from doxofylline. This regimen may improve lung function, reduce symptoms, and potentially allow for lower corticosteroid doses[3][4][6].